Market overview
The global artificial pancreas device market is worth USD 6.2 bn in 2026 and is forecast to reach USD 20.0 bn by 2036, growing at a 12.5% CAGR. United States is the largest country market and Tubed pump systems is the largest by pump type segment.
| Scope | Automated insulin delivery systems that link an insulin pump, glucose sensor and control algorithm, including tubed and patch pumps and their consumables, sold to people with diabetes. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 5.4 bn |
| Value 2026 | USD 6.2 bn |
| Value 2036 | USD 20.0 bn |
| CAGR 2026-2036 | 12.5% |
| Volume 2026 | 1,958 thousand users |
| Volume 2036 | 7,029 thousand users |
| Average price 2026 | USD 3,145 per user |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Artificial Pancreas Device market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 6.2 bn |
| 2027 | USD 6.9 bn |
| 2028 | USD 7.8 bn |
| 2029 | USD 8.8 bn |
| 2030 | USD 9.9 bn |
| 2031 | USD 11.1 bn |
| 2032 | USD 12.5 bn |
| 2033 | USD 14.0 bn |
| 2034 | USD 15.8 bn |
| 2035 | USD 17.8 bn |
| 2036 | USD 20.0 bn |
Artificial Pancreas Device market segmentation
By pump type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Tubed pump systems | 46.0% | 32.0% | USD 2.8 bn | 8.5% |
| Patch pump systems | 46.0% | 60.0% | USD 2.8 bn | 15.5% |
| Other and open-source systems | 8.0% | 8.0% | USD 492 mn | 12.5% |
By diabetes type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Type 1 diabetes | 74.0% | 57.4% | USD 4.6 bn | 9.7% |
| Type 2 diabetes on insulin | 20.0% | 37.0% | USD 1.2 bn | 19.6% |
| Other insulin-requiring diabetes | 6.0% | 5.6% | USD 369 mn | 11.7% |
By component
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Insulin pumps | 38.0% | 34.0% | USD 2.3 bn | 11.3% |
| Continuous glucose monitors | 34.0% | 36.0% | USD 2.1 bn | 13.1% |
| Control algorithm software | 16.0% | 19.0% | USD 985 mn | 14.4% |
| Infusion sets and consumables | 12.0% | 11.0% | USD 739 mn | 11.5% |
By algorithm type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hybrid closed loop | 68.0% | 56.0% | USD 4.2 bn | 10.3% |
| Advanced hybrid closed loop | 22.0% | 32.0% | USD 1.4 bn | 16.8% |
| Predictive low glucose suspend | 10.0% | 12.0% | USD 616 mn | 14.6% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Home users | 78.0% | 80.0% | USD 4.8 bn | 12.8% |
| Hospitals and clinics | 16.0% | 14.0% | USD 985 mn | 11.0% |
| Pediatric care centers | 6.0% | 6.0% | USD 369 mn | 12.5% |
Top 25 countries for artificial pancreas device by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 83.5% of 2026 revenue and the 25 countries below together hold 95.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 3.2 bn | 52.0% | USD 10.6 bn | 12.7% |
| 2 | Germany | USD 369 mn | 6.0% | USD 1.1 bn | 11.7% |
| 3 | United Kingdom | USD 308 mn | 5.0% | USD 980 mn | 12.3% |
| 4 | France | USD 246 mn | 4.0% | USD 740 mn | 11.6% |
| 5 | Canada | USD 246 mn | 4.0% | USD 780 mn | 12.2% |
| 6 | Australia | USD 215 mn | 3.5% | USD 720 mn | 12.8% |
| 7 | Italy | USD 154 mn | 2.5% | USD 440 mn | 11.1% |
| 8 | Spain | USD 154 mn | 2.5% | USD 460 mn | 11.6% |
| 9 | Netherlands | USD 123 mn | 2.0% | USD 400 mn | 12.5% |
| 10 | Japan | USD 123 mn | 2.0% | USD 360 mn | 11.3% |
| 11 | South Korea | USD 96 mn | 1.6% | USD 348 mn | 13.7% |
| 12 | Israel | USD 81 mn | 1.3% | USD 260 mn | 12.4% |
| 13 | Switzerland | USD 78 mn | 1.3% | USD 250 mn | 12.4% |
| 14 | Sweden | USD 65 mn | 1.1% | USD 210 mn | 12.4% |
| 15 | Belgium | USD 62 mn | 1.0% | USD 200 mn | 12.4% |
| 16 | Austria | USD 59 mn | 1.0% | USD 190 mn | 12.4% |
| 17 | Denmark | USD 52 mn | 0.8% | USD 168 mn | 12.5% |
| 18 | Brazil | USD 46 mn | 0.7% | USD 166 mn | 13.8% |
| 19 | Mexico | USD 34 mn | 0.6% | USD 124 mn | 13.7% |
| 20 | China | USD 33 mn | 0.5% | USD 106 mn | 12.5% |
| 21 | India | USD 26 mn | 0.4% | USD 96 mn | 13.7% |
| 22 | Ireland | USD 25 mn | 0.4% | USD 82 mn | 12.5% |
| 23 | Poland | USD 24 mn | 0.4% | USD 88 mn | 13.9% |
| 24 | Saudi Arabia | USD 21 mn | 0.3% | USD 76 mn | 13.8% |
| 25 | Taiwan | USD 18 mn | 0.3% | USD 68 mn | 13.9% |
| Rest of world | USD 295 mn | 4.8% | USD 948 mn | 12.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Medtronic
- Insulet
- Tandem Diabetes Care
- Dexcom
- Abbott
Group 2: Regional and specialist players
- Ypsomed
- Sequel Med Tech
- CamDiab
- Dana Diabetes Care
- Roche Diabetes Care
- Sooil Development
- MicroTech Medical
Group 3: Emerging and niche players
- Beta Bionics
- Diabeloop
- Medtrum
- Inreda Diabetic
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the artificial pancreas device market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.5% is calculated from the resulting values.
The market is divided by pump type, by diabetes type, by component, by algorithm type, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the artificial pancreas device market?
The global artificial pancreas device market is estimated at USD 5.4 bn in 2025 and USD 6.2 bn in 2026.
How fast will the artificial pancreas device market grow?
It is forecast to reach USD 20.0 bn by 2036, a compound annual growth rate of 12.5% from 2026, an increase of USD 13.8 bn.
Which country is the largest market for artificial pancreas device?
United States is the largest market by revenue at USD 3.2 bn in 2026, 52.0% of the global total. The three largest countries together hold 63.0%.
Which country is growing fastest?
Among the ten largest markets, Australia is growing fastest at 12.8% a year from 2026 to 2036.
Which artificial pancreas device segment is largest?
In the by pump type split, Tubed pump systems is the largest segment with 46.0% of 2026 revenue.
Who are the leading artificial pancreas device companies?
Global leaders include Medtronic, Insulet, Tandem Diabetes Care, Dexcom.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Single Use BioreactorUSD 6.2 bn · 12.0% CAGR
- Tissue EngineeringUSD 6.0 bn · 10.5% CAGR
- Good Manufacturing Practice ComplianceUSD 6.3 bn · 8.5% CAGR
- Liquid HandlingUSD 6.0 bn · 7.5% CAGR
- Cleanroom EquipmentUSD 6.0 bn · 8.0% CAGR
- Microsphere Drug DeliveryUSD 6.0 bn · 8.0% CAGR
- Retail ClinicUSD 6.3 bn · 5.3% CAGR
- UltrafiltrationUSD 6.4 bn · 9.5% CAGR
← Aquaculture Fungal Infection Treatment Ascites Fluid Removal Devices →